Pharmacological alteration of hyper-reactivity in rats with septal and hypothalamic lesions.
D000632:Aminopyrine / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000502:physiology; D001930:Brain Injuries; D002552:Cerebral Ventricles / Q000293:injuries; D002707:Chlordiazepoxide / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003496:Cyclazocine / Q000494:pharmacology; D004357:Drug Synergism; D007031:Hypothalamus / Q000293:injuries; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009269:Nalorphine / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010423:Pentazocine / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D014149:Tranquilizing Agents / Q000494:pharmacology*
D000700:Analgesics; D009292:Narcotic Antagonists; D014149:Tranquilizing Agents; D000632:Aminopyrine; D010862:Pilocarpine; D002707:Chlordiazepoxide; D009020:Morphine; D010830:Physostigmine; D010424:Pentobarbital; D003496:Cyclazocine; D010423:Pentazocine; D002746:Chlorpromazine; D009269:Nalorphine